Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
AssigneeSanofi
InventorsMathias Gebauer, Martin Michaelis, Danping Ding-Pfennigdorff, Anke M. Schulte, Daniel Ziemek, Christiane Metz-Weldmann
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of identifying a compound involved in pain, the use of Ctla2b nucleic acid or Ctla2b protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.
Claims15
A method of identifying a compound involved in pain, the method comprising the steps of:
- a) providing a test system comprising Ctla2b nucleic acid,
- b) contacting the test system with a test compound, and
- c) determining the effect of the test compound on the test system,
- wherein the test compound is identified as a compound involved in pain, when a significant effect of the test compound on the test system relative to a control is detected.
A method of identifying a compound involved in pain, the method comprising the steps of:
- a) providing a test system comprising Ctla2b protein or a functionally active variant thereof,
- a) contacting the test system with a test compound, and
- b) determining the effect of the test compound on the test system,
- wherein the test compound is identified as a compound involved in pain, when a significant effect of the test compound on the test system relative to a control is detected.
Use of Ctla2b nucleic acid for identifying a compound involved in pain.
Use of Ctla2b protein for identifying a compound involved in pain.
A method of diagnosing algesia, comprising the steps of
- a) determining the level expression of the Ctla2b gene in a subject's sample, and
- b) identifying the subject as algesic, if the level expression of the Ctla2b gene is increased in the subject's sample relative to a control.
Dependencies are inferred from the claim text.